Weight Loss on Semaglutide: Real Trial Data

The question almost everyone asks before starting semaglutide is the simplest one: how much weight will I lose? It is also the hardest to answer honestly, because the truthful response is a range, not a number. The trials that established semaglutide as an obesity treatment produced one of the strongest evidence bases the field has ever assembled — large, randomised, placebo-controlled studies with weight loss as a pre-specified endpoint. But what those studies report is an average, and the average conceals a spread of individual outcomes wide enough that two people on the same dose, for the same duration, can end up in very different places.

This article works through what the STEP program — the series of phase 3 trials that brought semaglutide into obesity medicine — actually showed: the headline weight-loss figures, the distribution of responses around the mean, the time course over which the loss accumulates, why it plateaus, and what happened when participants stopped. The aim is to replace the marketing number with a realistic picture. For the underlying biology of how the drug produces these effects, the complete guide to GLP-1 medications is the place to start; here the focus is squarely on the numbers.

The Headline Figure: About 15%

The defining trial is STEP 1, led by John Wilding at the University of Liverpool and published in the New England Journal of Medicine in 2021. It randomised 1,961 adults with overweight or obesity, but without type 2 diabetes, in a 2:1 ratio to once-weekly semaglutide titrated to 2.4mg or to placebo. Both groups received lifestyle counselling. Over 68 weeks — about sixteen months — the semaglutide group lost a mean of roughly 14.9% of body weight, against about 2.4% on placebo. The treatment difference, the part attributable to the drug itself rather than to the lifestyle support both groups received, was close to twelve percentage points (Wilding et al., 2021).

To put that in absolute terms: for someone starting at 100kg, a 15% loss is about 15kg. For someone starting at 220lb, it is roughly 33lb. This was, for a non-surgical intervention, without precedent. Before this generation of drugs, weight-loss medications generally delivered single-digit percentage reductions, and a mean of nearly 15% was not an incremental improvement on that baseline but a different order of magnitude. Daniel Drucker's 2018 account of GLP-1 pharmacology in Cell Metabolism had already mapped why the hormone was such a promising target; STEP 1 was the clinical payoff (Drucker, 2018). The mechanism specific to this drug is unpacked in how semaglutide works for weight loss, and a plain-English overview of the medication itself sits in semaglutide explained.

It is worth being precise about one thing the headline figure assumes: the full 2.4mg dose. That is the dose approved for weight management (sold as Wegovy), reached only after a gradual titration over roughly sixteen to twenty weeks. Lower doses, including the 1mg and 2mg doses more typical of the diabetes indication, produce correspondingly smaller weight loss. The 15% number describes people who reached and tolerated the full weight-management dose for the full trial duration — not everyone who picks up a prescription.

What the Average Hides: The Spread of Responses

A mean of 15% is a useful summary, but it is a poor prediction for any individual, because the responses around it are remarkably dispersed. STEP 1 reported the distribution explicitly, and it is the single most important thing to understand before starting.

About 86% of participants on semaglutide lost at least 5% of their body weight — the conventional threshold for a clinically meaningful response. Roughly 69% lost at least 10%, around 50% lost at least 15%, and about 32% lost 20% or more, a degree of loss that overlaps with what some bariatric surgery achieves. At the other end, a minority lost very little, and a small fraction did not respond meaningfully at all (Wilding et al., 2021). The same dose, the same duration, the same counselling — and outcomes ranging from essentially no change to a fifth of body weight gone.

Weight-loss threshold	Semaglutide 2.4mg	Placebo
Lost ≥5% of body weight	~86%	~32%
Lost ≥10%	~69%	~12%
Lost ≥15%	~50%	~5%
Lost ≥20%	~32%	~2%
Mean weight change (68 weeks)	~−14.9%	~−2.4%

Why the variation? The honest answer is that the trials do not fully identify in advance who falls where. Some of it reflects how high a dose a person can tolerate without limiting gastrointestinal side effects; some reflects differences in the underlying biology of appetite and energy expenditure; some reflects how much behavioural change accompanies the pharmacology. What the data make clear is that nobody should treat 15% as a personal forecast. It is the centre of a broad distribution, and a given person may land well above or well below it. Setting expectations against that distribution rather than against the mean is the substance of realistic weight-loss goals on GLP-1.

How Semaglutide Compares to Tirzepatide

Semaglutide is no longer the most potent option, and any honest account of the numbers has to say so. SURMOUNT-1, led by Ania Jastreboff at Yale and published in the NEJM in 2022, tested tirzepatide — a dual GLP-1/GIP agonist — in 2,539 adults with obesity (or overweight with a complication) and without diabetes, over 72 weeks. Mean weight loss was 15.0% on the 5mg dose, 19.5% on 10mg, and 20.9% on the highest 15mg dose, against 3.1% on placebo. More than half of those on the top dose lost more than 20% of their starting weight (Jastreboff et al., 2022).

The two drugs were studied in separate trials with somewhat different populations and durations, so head-to-head comparison from these numbers alone is imperfect. But the broad picture is consistent: tirzepatide's dual mechanism produces larger average loss than semaglutide's single-receptor action. That does not make semaglutide a poor choice — a mean of 15% remains a major clinical effect, and individual factors including tolerability, access, and cost properly drive the decision. It does mean that the "how much will I lose" question now has two different reference points depending on which drug is used.

The Time Course: When the Loss Happens

Weight does not come off evenly across the months. In STEP 1, the loss was fastest in the early-to-middle part of the trial, as the dose was titrated upward and appetite suppression deepened, and then progressively slowed. The curve is steep at first and flattens toward the end — most participants were still losing at 68 weeks, but the rate had declined substantially from its early pace.

This shape matters for expectations in two ways. First, the early weeks on low titration doses often produce only modest loss; the larger reductions arrive once the full dose is reached and sustained. People who judge the drug by the first month frequently underestimate it. Second, the flattening toward the end is not the drug ceasing to work — it is the approach to a new equilibrium, which is a different phenomenon, discussed next. The practical upshot is that semaglutide is a slow, cumulative intervention measured over a year or more, not a rapid one measured over weeks.

Why Weight Loss Plateaus

Almost everyone on semaglutide eventually reaches a point where the scale stops moving, often well before they expected and often at a weight higher than they hoped for. This plateau is one of the most common sources of disappointment, and it is widely misread as the drug failing. It is not.

The plateau reflects the body's defence of its weight catching up with the medication's effect on intake. When weight falls, the body mounts a coordinated counter-response. Rudolph Leibel and colleagues at Columbia demonstrated in 1995 that after a 10% weight loss, resting energy expenditure falls by more than body-size change alone predicts — the body quietly burns less (Leibel et al., 1995). Erin Fothergill's six-year follow-up of The Biggest Loser contestants found this adaptive reduction in metabolism still present years later (Fothergill et al., 2016). Manfred Müller's 2018 synthesis describes a homeostatic system that resists downward shifts in weight through coordinated changes in hunger, satiety, and energy expenditure (Müller et al., 2018).

Semaglutide works by countering the appetite side of that defence. But as weight falls, the energy-expenditure side of the defence strengthens, and eventually the drug-induced reduction in eating and the body's defensive reduction in burning meet at a new equilibrium. That equilibrium is the plateau. It is a sign the body has adapted, not that the medication has stopped working — and weight typically holds at the plateau as long as the drug is continued, rather than rebounding. The mechanics, and what can and cannot be done about it, are covered in detail in the GLP-1 weight-loss plateau.

What Happens If You Stop: The STEP 4 Data

The most consequential number in the entire dataset is not about how much weight comes off, but about what happens when the drug is withdrawn. The STEP 4 trial, led by Domenica Rubino and published in JAMA in 2021, was designed to answer exactly this. All participants took semaglutide for an initial twenty weeks, then were randomised either to continue the drug or to switch to placebo for a further forty-eight weeks.

The result was stark. The continuation group lost an additional 7.9% of body weight over the remaining period. The placebo group regained an average of 6.9% — roughly two-thirds of what they had lost during the run-in phase (Rubino et al., 2021). The longer-term follow-up told the same story: the STEP 1 trial extension, which tracked participants after the medication was withdrawn, found that much of the lost weight returned over the following year, with cardiometabolic improvements partly reversing alongside it (Wilding et al., 2022).

This is not a flaw peculiar to semaglutide. It is the biology of weight regain, which long predates these drugs. Priya Sumithran and colleagues showed in 2011 that a year after a very-low-calorie diet, appetite-regulating hormones remained dysregulated in the direction that favours regain — hunger signals elevated, satiety signals suppressed — long after the diet had ended (Sumithran et al., 2011). James Anderson's 2001 meta-analysis put the long-term consequence of dieting in numbers: across studies, people maintained only about 23% of their initial weight loss at five years (Anderson et al., 2001). The body defends its prior weight whether the loss was driven by diet or by medication.

Seen this way, semaglutide behaves like other chronic-disease treatments. It counters the biological defence of weight for as long as it is present; when it is removed, the defence reasserts itself, much as blood pressure rises again when antihypertensives are stopped. That reframes the duration question entirely — it is closer to the question one asks about cholesterol medication than about a course of antibiotics. Whether lower-dose or intermittent maintenance can hold weight off as effectively as full-dose continuation is being studied but is not yet established, a question taken up in the GLP-1 maintenance dose.

Setting Realistic Expectations

Pulling the data together suggests a small set of honest expectations to carry into treatment.

• Expect a range, not a number. The mean is about 15% at the full dose over roughly sixteen months, but your personal result could plausibly be anywhere from a few percent to over 20%. The 5% and 10% thresholds — reached by the large majority — are clinically meaningful in their own right, improving blood pressure, blood sugar, and other markers even when they fall short of a cosmetic goal.
• Expect it to be slow. Meaningful loss accumulates over a year or more, with the fastest phase arriving after the dose is titrated up, not in the first weeks.
• Expect a plateau. The scale will stop at some point, and that point may be higher than you hoped. This reflects the body reaching a defended equilibrium, not the drug failing.
• Expect the loss to depend on continuation. The STEP 4 data are unambiguous: stopping is typically followed by substantial regain, because the underlying biology was countered, not cured.

None of this is a reason for discouragement. A treatment that reliably produces double-digit percentage weight loss, with the strongest grade of trial evidence behind it, is a genuine advance. But the version of that treatment sold in headlines — a guaranteed, fast, permanent transformation — is not the version the trials describe. The trials describe a powerful, slow, individually variable intervention that works for as long as it is used. Understanding that distinction is the difference between disappointment and a realistic plan. For the broader research landscape these numbers sit within, the GLP-1 science cluster collects the related evidence in one place. As always, none of this is medical advice; decisions about starting, dosing, and continuing belong with a clinician who knows your history.